Theravance Biopharma
TBPH
TBPH
171 hedge funds and large institutions have $808M invested in Theravance Biopharma in 2026 Q1 according to their latest regulatory filings, with 40 funds opening new positions, 60 increasing their positions, 45 reducing their positions, and 35 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
less ownership
Funds ownership: →
13% less capital invested
Capital invested by funds: $927M → $808M (-$119M)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
93% less call options, than puts
Call options by funds: $847K | Put options by funds: $11.6M
Holders
171
Holding in Top 10
4
Calls
$847K
Puts
$11.6M
Top Buyers
| 1 | +$12.8M | |
| 2 | +$9.58M | |
| 3 | +$5.66M | |
| 4 |
6CM
683 Capital Management
New York
|
+$4.42M |
| 5 |
BlackRock
New York
|
+$4.35M |
Top Sellers
| 1 | -$11.2M | |
| 2 | -$6.57M | |
| 3 | -$6.34M | |
| 4 |
HIM
Hillsdale Investment Management
Toronto,
Ontario, Canada
|
-$5.77M |
| 5 |
D.E. Shaw & Co
New York
|
-$5.41M |
